Personal information

Neuroscience, Fragile X syndrome, Glutamate, Synaptosomes, Presynapse
Spain, United Kingdom

Biography

After finishing Pharmacy degree I decided to study a Masters in Neuroscience. During that period I met Professor María Jesús Oset and Doctor José Luis Marco and collaborated with them in a project related to the development of novel pyranotacrines as interesting candidates for the treatment of Alzheimer´s disease (García-Font N. et al., 2016 ‎Eur. J. Med. Chem).
When I finished that Masters, Professor Oset encouraged me to continue with the Doctorate in Biochemistry under the supervision of Professor José Sánchez-Prieto about Fragile X syndrome, which is an inherited form of autism. As part of this group, my mission has been the study of three metabotropic receptors (CB1, beta adrenergic and Metabotropic glutamate 7) located in the presynapse. I discovered two relevant alterations in the beta adrenergic pathway that affect the enhancement of glutamate release not only in the cerebral cortex (García-Font N. et al., 2019. Neurobiol. Dis.) but also in cerebellum. All the results were gathered together in my Thesis work which was defended in November of 2019. After that, I have continued with my postdoc in Edinburgh with Professor Richard Morris. I am conducting a project about social alterations and possible treatments for fragile X syndrome.
I have published 8 scientific papers (two of them as first author) and one dissemination article. I presented 6 oral communications and 1 poster in national meetings and I obtained two prizes: accésit of the IV Jornada de Investigación en Doctorado VetInDoc PhDay and Premio Antonio Doadrio López of the Real Academia Nacional de Farmacia. I also taught a seminar in Masters of Neuroscience for four years and collaborated in the laboratory practices in Pharmacy and Veterinary degrees.

Activities

Employment (2)

University of Edinburgh: Edinburgh, GB

2021-01-01 to present | Postdoctoral Research Fellow (Centre for Discovery Brain Sciences)
Employment
Source: Self-asserted source
García-Font N

Universidad Complutense de Madrid: Madrid, Comunidad de Madrid, ES

2020-01-01 to 2020-12-01 | Investigador postdoctoral (Bioquímica y Biología Molecular)
Employment
Source: Self-asserted source
García-Font N

Education and qualifications (3)

Universidad Complutense de Madrid: Madrid, Comunidad de Madrid, ES

2014 to 2019-11-21 | Doctorado en Bioquímica, Biología Molecular y Biomedicina (Bioquímica y Biología Molecular)
Education
Source: Self-asserted source
García-Font N

Universidad Complutense de Madrid: Madrid, Comunidad de Madrid, ES

2013 to 2014 | Máster en Neurociencia
Education
Source: Self-asserted source
García-Font N

Universidad Complutense de Madrid: Madrid, Comunidad de Madrid, ES

2008 to 2013 | Licenciatura en Farmacia
Education
Source: Self-asserted source
García-Font N

Works (9)

Ca2+ imaging of self and other in medial prefrontal cortex during social dominance interactions in a tube test

Proceedings of the National Academy of Sciences
2022-08-02 | Journal article
Contributors: Nuria Garcia-Font; Rufus Mitchell-Heggs; Kapil Saxena; Carolin Gabbert; Georgina Taylor; Giulia Mastroberardino; Patrick A. Spooner; Francesco Gobbo; Julia K. Dabrowska; Sumantra Chattarji et al.
Source: check_circle
Crossref

Neuroprotection by Phytoestrogens in the Model of Deprivation and Resupply of Oxygen and Glucose In Vitro: The Contribution of Autophagy and Related Signaling Mechanisms

Antioxidants
2020-06-22 | Journal article
Contributors: Giuseppe Abbruzzese; Javier Morón-Oset; Sabela Díaz-Castroverde; Nuria García-Font; Cesáreo Roncero; Francisco López-Muñoz; José Luis Marco Contelles; María Jesús Oset-Gasque
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Control presináptico por receptores acoplados a protéınas G, GPCRs, en un ratón modelo del śındrome X frágil

2019 | Dissertation or Thesis
Source: Self-asserted source
García-Font N

The loss of β adrenergic receptor mediated release potentiation in a mouse model of fragile X syndrome

Neurobiology of disease
2019 | Journal article
Source: Self-asserted source
García-Font N

Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer’s disease

European journal of medicinal chemistry
2016 | Journal article
Source: Self-asserted source
García-Font N

Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease

European journal of medicinal chemistry
2016 | Journal article
Source: Self-asserted source
García-Font N

Pyranopyrazolotacrines as nonneurotoxic, Aβ-anti-aggregating and neuroprotective agents for Alzheimer's disease

Future medicinal chemistry
2015 | Journal article
Source: Self-asserted source
García-Font N

Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrines {11-amino-12-aryl-8, 9, 10, 12-tetrahydro-7H-chromeno [2, 3-b] quinolin-3-ols} for the potential prevention and treatment of Alzheimer's disease

European journal of medicinal chemistry
2014 | Journal article
Source: Self-asserted source
García-Font N

Posibles efectos beneficiosos para la salud del fruto de mangostán

Revista de fitoterapia
2011 | Journal article
Source: Self-asserted source
García-Font N